Withus Pharmaceutical Co.,LTD. (330350.KQ) Stock
Withus Pharmaceutical Co.,LTD.

Company profile
Withus Pharmaceutical reported revenue of 106.44 billion KRW for fiscal year 2025, up 3.6% from fiscal year 2024, and net income of 4.97 billion KRW. That is a net profit margin of 4.7% for fiscal year 2025. Our analysis of its filings shows revenue growing from 80.12 billion KRW in fiscal year 2023 to 106.44 billion KRW in fiscal year 2025, 15.3% a year on average.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Withus Pharmaceutical Co.,LTD.
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products. The company was previously known as Withers Medipharm Co., Ltd. and changed its name to WITHUS PHARMACEUTICAL Co.,LTD. in October 2007. WITHUS PHARMACEUTICAL Co.,LTD. was founded in 2004 and is headquartered in Seoul, South Korea.
Largest shareholders
- Dae-Young Sung52.44 %52.44%
- Withus Pharmaceutical Co., Ltd. ESOA0.80%
- Kwang-Young Kwon0.4341 %0.43%
- Gwang-yeong Lee0.0795 %0.08%
- Withus Pharmaceutical Co.,Ltd.0.02%
Share of the company, as of September 25, 2026
Leadership
- Dae-young Sung — CEO & Executive Director, 66
- GwangYoung Kwon — VP & Executive Director, 64
How much revenue does Withus Pharmaceutical make?
Withus Pharmaceutical reported 106.44 billion KRW in revenue for fiscal year 2025, up 3.6% from 102.72 billion KRW in fiscal year 2024.
What companies are similar to Withus Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Handok Inc. (002390.KS), Jeil Pharma Holdings Inc (002620.KS), Dong Sung Bio Pharm.Co.,Ltd. (002210.KS), Korea Pharma Co., Ltd. (032300.KQ).
How has Withus Pharmaceutical's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 57.42 billion KRW; FY2022, 64.68 billion KRW; FY2023, 80.12 billion KRW; FY2024, 102.72 billion KRW; FY2025, 106.44 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Withus Pharmaceutical Co.,LTD. (330350.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/330350.KQ